Cost of Immunotherapy for Breast and Gynaecological Cancers — Eligibility First, Then the Number

No. Most women treated for breast cancer in India never receive immunotherapy. Hormone-receptor-positive and HER2-positive breast cancers are treated along other pathways entirely. Immunotherapy is considered mainly in triple-negative breast cancer, and in selected advanced or recurrent cervical, endometrial and ovarian disease. Eligibility is settled before any price is worth discussing.

• In breast cancer, the subtype decides before anything else — roughly two-thirds of breast cancers are hormone-receptor-positive, and those are managed with surgery, radiation, hormone tablets and chemotherapy where it is needed. Checkpoint immunotherapy has no routine place in that group. Who is actually eligible for immunotherapy in breast cancer sets out the boundary in detail.
• HER2-targeted treatment is not the same thing — families often use the word immunotherapy for both. A HER2-targeted antibody is a different class of drug, on a different price ladder, and biosimilar entry has already changed that ladder considerably. How much biosimilars actually save explains why the same treatment can be quoted at very different figures.
• Triple-negative breast cancer is where the question is real — commonly cited as about 10 to 15 per cent of breast cancers. Even inside that group, a PD-L1 score on the tumour usually has to clear a defined threshold, and the setting has to match current NCCN or ESMO guidance. Immunotherapy for triple-negative breast cancer covers what the threshold means.
• In gynaecological cancers, stage and biomarker decide, not the organ — advanced or recurrent cervical cancer and endometrial cancer are where it is most often discussed, with mismatch-repair status doing most of the deciding in endometrial disease. In ovarian cancer the evidence remains immature, and a plan that assumes otherwise should be questioned.
• Fitness and immune history are weighed honestly — an active autoimmune condition, a previous organ transplant or ongoing high-dose steroids can make immunotherapy unsuitable regardless of the tumour result.

A cycle is priced by the drug, not by the cancer. As of August 2026, one cycle of a checkpoint inhibitor runs roughly ₹50,000 to ₹1,50,000 for a domestically manufactured or biosimilar product, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Day care, blood tests and scans are billed on top. Indicative only.

Why two centres can quote the same regimen very differently

Most of the gap is not the drug. It is which product was chosen, whether the dose is flat or weight-based, and which lines a quote leaves out until the day of treatment.

Immunotherapy is administered as day care at CION centres, so a routine cycle carries no inpatient bed charge — if a quote includes one, ask what it is for. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and is billed by the imaging centre directly, so it will not appear on a CION estimate at all. Ask every centre you approach who raises that bill. How to compare two quotes line by line and whether weight-based or fixed dosing changes what you pay are the two checks that move the number most.

Testing comes first, and you pay for it first. As of August 2026, a PD-L1 stain runs roughly ₹6,000 to ₹12,000 and mismatch-repair immunohistochemistry roughly ₹4,000 to ₹8,000. Both are one-time, and both are usually run on tissue you have already given. That result decides whether a lakh-per-cycle conversation applies at all.

Two testing costs families are quoted and do not always need

An HPV test tells you about the cause of a cervical cancer. It does not decide whether immunotherapy can be used, so it should not appear on an eligibility quote as though it does — what HPV status does and does not change covers the distinction. A broad sequencing panel is the other one: worth doing in defined situations, and an expensive default when a single stain would have answered the question. Which biomarker tests you actually need and what they cost sets out how to ask, and whether testing is covered by insurance or a scheme is worth checking before you pay out of pocket. For a younger woman, fertility preservation, where it applies, is a separate cost and a separate conversation — and one that has to happen before treatment starts, not after.

There is no single total, because the length is not fixed in advance. On three-weekly dosing, three months is about four cycles and a year about seventeen. Budget against the three-month and six-month rows first, then revisit the figure at every response scan. Indicative, as of August 2026.

Where chemotherapy runs alongside the immunotherapy, as it commonly does in triple-negative breast and advanced cervical regimens, add roughly ₹8,000 to ₹30,000 per cycle for the cycles where it applies, plus more spending on anti-nausea and other supportive medicines. Then add day care and pre-cycle bloods for every cycle, and a response scan every eight to twelve weeks. All indicative, as of August 2026. For the national picture across all cancers see what a full course actually comes to in India, and the costs nobody budgets for covers travel, attendant stay and lost workdays, which for a family travelling into Hyderabad are rarely small.

Government schemes work to fixed package ceilings, and high-cost immunotherapy commonly sits above them, so cover is often partial. Private policies usually pay for day-care infusion, subject to sub-limits and pre-authorisation. Manufacturer programmes and tax relief cover parts of the rest. None of this is a promise of cover.

• Aarogyasri, in Telangana and Andhra Pradesh — surgery, radiation and chemotherapy packages for breast and gynaecological cancers are well established, and high-cost immunotherapy sits in a different bracket altogether. What the scheme funds and what it does not explains how to ask for the current ceiling in writing rather than over a counter.
• Ayushman Bharat PM-JAY — the same package-ceiling logic applies nationally. Ayushman Bharat and immunotherapy coverage covers what the scheme reaches.
• CGHS, ECHS and ESI — these run on approved rate lists plus prior approval. The approval step often takes longer than the gap between two cycles, so start the paperwork before treatment begins.
• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive. Where immunotherapy claims actually fail is worth reading before you file the first one.
• Manufacturer patient-assistance programmes — several run assistance or dose-support schemes in India. Eligibility varies, documentation takes time, and applications usually have to be made before cycle one rather than midway. How they work and how to apply.
• Section 80DDB tax relief — a deduction on documented treatment expenditure, claimed with the right certificate. What you can actually claim.
• Choosing a domestically manufactured product — where one exists and is clinically appropriate, usually the single largest reduction available on this bill. It is a conversation for your oncologist, not a decision to take alone.
• Crowdfunding — used widely and unevenly. What actually works, and what does not.

Because the per-cycle price is much the same everywhere, and the eligibility answer is not. Lung cancer is the clearest contrast: immunotherapy is used far more often there, for longer, and in more settings. If you are comparing what a relative was told, these pages show why the two plans differ.

• Immunotherapy for Small Cell Lung Cancer — a cancer where immunotherapy is combined with chemotherapy from the start, so the early cycles carry two drug lines at once, exactly as they do in a triple-negative breast regimen.
• Immunotherapy After Chemoradiation for Stage 3 Lung Cancer — the clearest example of a course with a planned ceiling, which is what makes a total possible to budget rather than open-ended.
• Immunotherapy for Lung Cancer in Smokers vs Non-Smokers — a reminder that who a treatment suits is decided by tumour biology, not by how common the cancer is.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring and cost counselling fit together as one pathway.

A Number Your Family Can Actually Plan Against

We put the eligibility answer and the indicative estimate in writing, dated, including the lines most quotes leave out.